New Stock News | Shenzhen Forms Syntron Information (300468.SZ) is planning a Hong Kong IPO. The China Securities Regulatory Commission requires clarification on whether the funds raised will involve domestic and foreign investment projects.
On January 30, the China Securities Regulatory Commission announced the requirements for supplementary materials for overseas issuance and listing filings (January 26, 2026 - January 30, 2026).
On January 30th, the China Securities Regulatory Commission announced the disclosure of supplementary materials requirements for overseas issuance and listing filing (January 26, 2026 - January 30, 2026). The CSRC requested Shenzhen Forms Syntron Information (300468.SZ) to provide further details on whether the funds raised are related to domestic and overseas investment projects, as well as the relevant approval, examination or filing procedures followed. In accordance with the "Regulatory Rules Application Guidelines - Overseas Issuance and Listing No. 2", the issuer should explain the overall situation of overseas operations. According to the disclosure made by the Hong Kong Stock Exchange on December 24, 2025, Shenzhen Forms Syntron Information submitted an IPO application to the Hong Kong Stock Exchange, with CMB International and Guosen (Hong Kong) as its joint sponsors.
The prospectus shows that Shenzhen Forms Syntron Information is a financial technology services provider rooted in the Greater Bay Area and deeply involved in the banking industry, providing financial technology software development, consulting, and system integration services to banks, regulatory agencies, and other financial institutions in mainland China, Hong Kong, and Southeast Asia, helping them advance their digital transformation.
Related Articles

New Stock Preview | From "Deep Squatting" in Performance to Global Leapfrogging: Decoding the Breakthrough Logic of Sirio Pharma (300791.SZ)

From the sharp decline in the entrance to the "doji star", is the reversal of the low-stage consolidation of INNOGEN-B (02591) imminent?

New stock preview | Hujia Technology: Dual pressure of single brand and online dependence Can high-tech profit margins continue?
New Stock Preview | From "Deep Squatting" in Performance to Global Leapfrogging: Decoding the Breakthrough Logic of Sirio Pharma (300791.SZ)

From the sharp decline in the entrance to the "doji star", is the reversal of the low-stage consolidation of INNOGEN-B (02591) imminent?

New stock preview | Hujia Technology: Dual pressure of single brand and online dependence Can high-tech profit margins continue?

RECOMMEND

Multiple A‑Share Companies Update Hong Kong IPO Progress Since Start Of Year
30/01/2026

Mainland Pharmaceutical Companies Rush To Hong Kong, Over 10 Firms Queue For IPO
30/01/2026

2026 Hong Kong Market Faces Unlocking Peak: HKD 1.6 Trillion In Restricted Shares To Be Released, How Will The Market Respond?
30/01/2026


